These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Correction of defects responsible for impaired Qa-2 class Ib MHC expression on melanoma cells protects mice from tumor growth. Chiang EY; Henson M; Stroynowski I J Immunol; 2003 May; 170(9):4515-23. PubMed ID: 12707328 [TBL] [Abstract][Full Text] [Related]
24. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response. Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214 [TBL] [Abstract][Full Text] [Related]
25. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules. Li H; Ou X; Xiong J Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598 [TBL] [Abstract][Full Text] [Related]
26. Antitumor effects of the combination therapy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice. Lasek W; Mackiewicz A; Czajka A; Switaj T; Goł b J; Wiznerowicz M; Korczak-Kowalska G; Bakowiec-Iskra EZ; Gryska K; Izycki D; Jakóbisiak M Cancer Gene Ther; 2000 Dec; 7(12):1581-90. PubMed ID: 11228537 [TBL] [Abstract][Full Text] [Related]
27. Vaccination with B7-1+ tumor and anti-adhesion therapy with RGD pseudo-peptide (FC-336) efficiently induce anti-metastatic effect. Fujii H; Inobe M; Hayakawa Y; Kimura F; Murakami M; Onishi Y; Azuma I; Uede T; Saiki I Clin Exp Metastasis; 1998 Feb; 16(2):141-8. PubMed ID: 9514095 [TBL] [Abstract][Full Text] [Related]
28. Augmentation of therapeutic antitumor immunity by B16F10 melanoma cells transfected by interferon-gamma and allogeneic MHC class I cDNAs. Lim YS; Kang BY; Kim EJ; Kim SH; Hwang SY; Kim TS Mol Cells; 1998 Oct; 8(5):629-36. PubMed ID: 9856353 [TBL] [Abstract][Full Text] [Related]
29. Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy. Xu X; Sun Q; Yu X; Zhao L Virus Res; 2017 Apr; 233():35-41. PubMed ID: 28286036 [TBL] [Abstract][Full Text] [Related]
30. A new mouse model of experimental melanoma for vaccine and lymphokine therapy. Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134 [TBL] [Abstract][Full Text] [Related]
31. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. Mansour M; Pohajdak B; Kast WM; Fuentes-Ortega A; Korets-Smith E; Weir GM; Brown RG; Daftarian P J Transl Med; 2007 Apr; 5():20. PubMed ID: 17451606 [TBL] [Abstract][Full Text] [Related]
32. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864 [TBL] [Abstract][Full Text] [Related]
33. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105 [TBL] [Abstract][Full Text] [Related]
34. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372 [TBL] [Abstract][Full Text] [Related]
35. Further studies of the therapeutic effects of murine melanoma-specific monoclonal antibodies. Law LW; Vieira WD; Hearing VJ; Gersten DM Biochim Biophys Acta; 1994 Apr; 1226(1):105-9. PubMed ID: 7908833 [TBL] [Abstract][Full Text] [Related]
36. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. Vijayakumar G; Palese P; Goff PH EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387 [TBL] [Abstract][Full Text] [Related]
37. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013 [TBL] [Abstract][Full Text] [Related]
38. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination]. Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746 [TBL] [Abstract][Full Text] [Related]
39. Decreased adhesion to endothelial cells and matrix proteins of H-2Kb gene transfected tumour cells. Lauri D; De Giovanni C; Biondelli T; Lalli E; Landuzzi L; Facchini A; Nicoletti G; Nanni P; Dejana E; Lollini PL Br J Cancer; 1993 Nov; 68(5):862-7. PubMed ID: 7692918 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of melanoma-associated antigen expression and ecotropic retrovirus production in B16BL6 melanoma cells transfected with major histocompatibility complex class I genes. Li M; Muller J; Xu F; Hearing VJ; Gorelik E Cancer Res; 1996 Oct; 56(19):4464-74. PubMed ID: 8813142 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]